PALO ALTO, Calif., March 24, 2020 /PRNewswire/ -- Kodiak
Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical
company specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that the company
received full registration of their trademarks "Kodiak" and "Kodiak
Sciences" from the U.S. Patent and Trademark Office for the
exclusive use of Kodiak Sciences Inc. and its subsidiaries.
"Obtaining exclusive trademark rights over 'Kodiak' and 'Kodiak
Sciences' strengthens recognition of Kodiak as a leader in the
research and development of medicines to treat and prevent retinal
disease," said John Borgeson, Chief
Financial Officer at Kodiak Sciences. "These trademarks support our
efforts to protect our proprietary rights and to compete
effectively in global markets of interest, as we continue to
accelerate development of KSI-301 and our pipeline built with our
proprietary ABC Platform."
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a clinical stage biopharmaceutical
company specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. Founded in 2009, we are focused
on bringing new science to the design and manufacture of next
generation retinal medicines to prevent and treat the leading
causes of blindness globally. Our ABC Platform™ uses molecular
engineering to merge the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration, a leading cause of blindness in elderly
patients, and diabetic eye diseases, a leading cause of blindness
in working-age patients. Kodiak has leveraged its ABC Platform to
build a pipeline of product candidates in various stages of
development including KSI-501, our bispecific anti-IL-6/VEGF
biopolymer conjugate for the treatment of neovascular retinal
diseases with an inflammatory component, and we are expanding our
early research pipeline to include ABC Platform based triplet
inhibitors for multifactorial retinal diseases such as dry AMD and
glaucoma. Kodiak is based in Palo Alto, CA. For more
information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC
Platform™ and the Kodiak logo are registered trademarks or
trademarks of Kodiak Sciences Inc. in various global
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-and-kodiak-sciences-trademarks-registered-to-kodiak-sciences-inc-for-its-exclusive-use-301027042.html
SOURCE Kodiak Sciences Inc.